The immune response to the hepatitis B virus (HBV) vaccine in newborns of hepatitis B e antigen (HBeAg)-positive or HBeAg-negative mothers is the subject of Huang et al. The authors report no correlation between the HBeAg status of the mothers/cord blood and the newborns immune response to the vaccine, but, unfortunately, draw unfounded conclusions regarding the tolerogenic potential of in utero exposure to HBeAg. In this reply, I address the possible influence of in utero exposure to the HBeAg, and briefly review other characteristics of the HBeAg, that may promote HBV chronicity. I argue that the function of HBeAg should no longer be considered “unknown” and that immunotolerance/immunomodulation represent the dominant functions of the HBeAg in viral–host interactions.
CITATION STYLE
Milich, D. R. (2019). Is the function of the HBeAg really unknown? Human Vaccines and Immunotherapeutics, 15(9), 2187–2191. https://doi.org/10.1080/21645515.2019.1607132
Mendeley helps you to discover research relevant for your work.